Selexis SA and Hoba Therapeutics Team Up to Advance Hoba’s Investigational Neuropathic Pain…
Selexis SA and Hoba Therapeutics announced that they have entered into an agreement to advance the development of Hoba’s clinical candidate HB-086 (rhMeteorin) for the treatment of…
Read More...
Read More...
